GlassScriptPhysician profile
Khalid Al-Talib
NPI 1194711846
$2,682.57
in general payments reported to CMS, 2019-2025
23 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $291 · 2021: $92.88 · 2022: $304 · 2023: $553 · 2024: $562 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $88.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.00 |
| Education | $88.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $266.14 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $249.33 | 2022-2025 | Filspari |
| Amgen INC. | $218.30 | 2019-2024 | Tavneos |
| Akebia Therapeutics INC | $217.67 | 2019-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $186.89 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $186.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $181.69 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $177.69 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $134.95 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $117.60 | 2022-2024 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $108.22 | 2019-2024 | Velphoro |
| Mallinckrodt Hospital Products INC. | $100.37 | 2020-2024 | Acthar |
| Bard Peripheral Vascular, INC. | $96.33 | 2019 | |
| Nxstage Medical, INC. | $81.14 | 2023-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Ani Pharmaceuticals, INC. | $74.66 | 2022-2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $61.51 | 2022-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $58.43 | 2024-2025 | Jynarque |
| Ardelyx, INC. | $55.65 | 2024-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $25.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $24.42 | 2020 | |
| Novo Nordisk INC | $24.37 | 2025 | Wegovy |
| Genzyme Corporation | $18.96 | 2019 | |
| Scpharmaceuticals INC. | $17.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Al-Talib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.